Equities research analysts at StockNews.com started coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT – Get Free Report) in a report issued on Sunday. The firm set a “hold” rating on the stock ...

Panelists discuss exciting updates on Bruton tyrosine kinase (BTK) inhibitors from the 2024 American Society of Hematology ...

Is Whispeara right for you? Find out through in-depth reviews on its ability to support ear health and brain function!

Faculty of Science, Department of Chemistry, Fırat University, Elazig 23169, Turkey ...

Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to ...

A phase III study testing the role of proactive coaching on patient reported outcome in advanced or metastatic renal cell carcinoma treated with sunitinib or a combination of axitinib + pembrolizumab ...

Cogent Biosciences (NASDAQ:COGT – Get Free Report) is projected to release its earnings data before the market opens on ...

Sellas Life Sciences has reported the multicentre Phase IIa trial data of a highly selective cyclin-dependent kinase 9 (CDK9) ...

Exelixis’ next-generation tyrosine kinase inhibitor zanzalintinib is being tested for colorectal cancer, renal cell carcinoma ...

Patients treated with tyrosine kinase inhibitors received olanzapine to address adverse effects including nausea/vomiting, ...

Paraneoplastic and symptomatic score for prediction of overall and cancer-specific survival in patients with renal cell carcinoma. This is an ASCO Meeting Abstract from the 2025 ASCO Genitourinary ...